243 related articles for article (PubMed ID: 34851157)
21. In Vitro and In Vivo Activities of a Bi-Aryl Oxazolidinone, RBx 11760, against Gram-Positive Bacteria.
Barman TK; Kumar M; Mathur T; Chaira T; Ramkumar G; Kalia V; Rao M; Pandya M; Yadav AS; Das B; Upadhyay DJ; Hamidullah ; Konwar R; Raj VS; Singh H
Antimicrob Agents Chemother; 2016 Dec; 60(12):7134-7145. PubMed ID: 27645240
[TBL] [Abstract][Full Text] [Related]
22. Semi-mechanistic PK/PD modelling of meropenem and sulbactam combination against carbapenem-resistant strains of Acinetobacter baumannii.
Mohd Sazlly Lim S; Heffernan AJ; Zowawi HM; Roberts JA; Sime FB
Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1943-1952. PubMed ID: 33884516
[TBL] [Abstract][Full Text] [Related]
23. Synergistic Activity of Colistin/Fosfomycin Combination against Carbapenemase-Producing
Wang J; He JT; Bai Y; Wang R; Cai Y
Biomed Res Int; 2018; 2018():5720417. PubMed ID: 29850537
[TBL] [Abstract][Full Text] [Related]
24. In vitro synergy with fosfomycin plus doxycyclin against linezolid and vancomycin-resistant Enterococcus faecium.
Davis H; Brown R; Ashcraft D; Pankey G
J Glob Antimicrob Resist; 2020 Sep; 22():78-83. PubMed ID: 32007618
[TBL] [Abstract][Full Text] [Related]
25. The Synergistic Activity of Rhamnolipid Combined with Linezolid against Linezolid-Resistant
Chang Q; Chen H; Li Y; Li H; Yang Z; Zeng J; Zhang P; Ge J; Gao M
Molecules; 2023 Nov; 28(22):. PubMed ID: 38005351
[TBL] [Abstract][Full Text] [Related]
26. Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients.
Dong H; Wang X; Dong Y; Lei J; Li H; You H; Wang M; Xing J; Sun J; Zhu H
Int J Antimicrob Agents; 2011 Oct; 38(4):296-300. PubMed ID: 21741222
[TBL] [Abstract][Full Text] [Related]
27. Increasing Linezolid-resistant Enterococcus in a Children's Hospital.
Bagga B; Buckingham S; Arnold S; Nesbitt A; Guimera D; Lee K
Pediatr Infect Dis J; 2018 Mar; 37(3):242-244. PubMed ID: 29189675
[TBL] [Abstract][Full Text] [Related]
28. Optimization of linezolid treatment regimens for Gram-positive bacterial infections based on pharmacokinetic/pharmacodynamic analysis.
Yang M; Zhang J; Chen Y; Liang X; Guo Y; Yu J; Zhu D; Zhang Y
Future Microbiol; 2017 Jan; 12():39-50. PubMed ID: 27922745
[TBL] [Abstract][Full Text] [Related]
29. Dispersal of linezolid-resistant enterococci carrying poxtA or optrA in retail meat and food-producing animals from Tunisia.
Elghaieb H; Freitas AR; Abbassi MS; Novais C; Zouari M; Hassen A; Peixe L
J Antimicrob Chemother; 2019 Oct; 74(10):2865-2869. PubMed ID: 31243458
[TBL] [Abstract][Full Text] [Related]
30. Activity of linezolid in an in vitro pharmacokinetic-pharmacodynamic model using different dosages and Staphylococcus aureus and Enterococcus faecalis strains with and without a hypermutator phenotype.
Ba BB; Arpin C; Bikie Bi Nso B; Dubois V; Saux MC; Quentin C
Antimicrob Agents Chemother; 2010 Apr; 54(4):1443-52. PubMed ID: 20100878
[TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamic Analysis of Meropenem and Fosfomycin Combination Against Carbapenem-Resistant
Mohd Sazlly Lim S; Heffernan AJ; Roberts JA; Sime FB
Microb Drug Resist; 2021 Apr; 27(4):546-552. PubMed ID: 32898467
[No Abstract] [Full Text] [Related]
32. In vitro activity of linezolid alone and combined with other antibiotics against clinical enterococcal isolates.
Beitdaghar M; Ahmadrajabi R; Karmostaji A; Saffari F
Wien Med Wochenschr; 2019 Jun; 169(9-10):215-221. PubMed ID: 28924925
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-β-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model.
Zykov IN; Samuelsen Ø; Jakobsen L; Småbrekke L; Andersson DI; Sundsfjord A; Frimodt-Møller N
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29581117
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity of fosfomycin in combination with linezolid against clinical isolates of methicillin-resistant Staphylococcus aureus.
Xu-hong Y; Falagas ME; Dong W; Karageorgopoulos DE; De-feng L; Rui W
J Antibiot (Tokyo); 2014 May; 67(5):369-71. PubMed ID: 24517925
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
Hall AD; Steed ME; Arias CA; Murray BE; Rybak MJ
Antimicrob Agents Chemother; 2012 Jun; 56(6):3174-80. PubMed ID: 22470111
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of single and multiple oral doses of fosfomycin against Pseudomonas aeruginosa urinary tract infections in a dynamic in vitro bladder infection model.
Abbott IJ; van Gorp E; Wijma RA; Dekker J; Croughs PD; Meletiadis J; Mouton JW; Peleg AY
J Antimicrob Chemother; 2020 Jul; 75(7):1879-1888. PubMed ID: 32361749
[TBL] [Abstract][Full Text] [Related]
37. Distribution of the optrA gene in Enterococcus isolates at a tertiary care hospital in China.
Zhou W; Gao S; Xu H; Zhang Z; Chen F; Shen H; Zhang C
J Glob Antimicrob Resist; 2019 Jun; 17():180-186. PubMed ID: 30641287
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of Vancomycin with Fosfomycin against Vancomycin-Resistant Enterococcus Strains Using Agar Dilution Method.
Aktas G
Clin Lab; 2021 Jan; 67(1):. PubMed ID: 33491411
[TBL] [Abstract][Full Text] [Related]
39. In vitro activity of fosfomycin tromethamine and linezolid against vancomycin-resistant Enterococcus faecium isolates.
Cilli F; Pullukcu H; Aydemir S; Sipahi OR; Tasbakan M; Turhan A; Ulusoy S
Int J Antimicrob Agents; 2008 Mar; 31(3):297-8. PubMed ID: 18180144
[No Abstract] [Full Text] [Related]
40. Evaluation of Activity and Emergence of Resistance of Polymyxin B and ZTI-01 (Fosfomycin for Injection) against KPC-Producing Klebsiella pneumoniae.
Diep JK; Sharma R; Ellis-Grosse EJ; Abboud CS; Rao GG
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
